Prosthetic Rehabilitation with Palatal Lift/Augmentation in a Patient with Neurologic/Motor Deficit Due To Cancer Therapy for Chondrosarcoma

Asfar, Midhat M.; Hutcheson, Katherine A.; Won, Alexander M.

doi:10.1111/jopr.12990

Cited by 9 publications

(5 citation statements)

References 15 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, chemotherapy and radiotherapy are not the mainstay therapies for chondrosarcoma. The primary goal is to better understand the characteristics of conventional chondrosarcomas since Amer et al [13,22] reviewed and described non-conventional chondrosarcomas. In the present study, we identi ed prognostic factors of chondrosarcoma based on data from the SEER database from 2010 to 2016, which was veri ed using data from 2007 to 2009.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Gao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Conventional chondrosarcoma, a rare type of bone tumor, was resistant to chemotherapy and radiation therapy, so more characteristics were needed. In clinic, the use of small series and single-institution studies have limited the investigation of chondrosarcoma. The Surveillance, Epidemiologic, and End Results is the most complete and comprehensive database worldwide. Based on this database, the study aimed to collect clinicopathological features and detect the prognosis of patients with conventional chondrosarcoma. Methods: Clinicopathologic and survival data of 782 patients from 2010 to 2016 and 353 patients from 2007 to 2009 were downloaded and analyzed. Overall survival was analyzed using the Kaplan-Meier method and verified by univariable Cox regression, and independent prognostic factors were assessed using the multi-variable Cox regression hazards model. Then, nomogram was established and the one-, three-, and five-year survival rates could be calculated with the nomogram. Competitive risk models were conducted to identify prognostic risk factors related to competitive endpoint events in patients with conventional chondrosarcoma. Results: In total, 361 extremities, 360 axial bones, and 61 cranial samples were collected from the 2010 to 2016 cohort. The median survival time of patients with conventional chondrosarcoma was 35 months, and the independent prognostic factors were sex, grade, surgery, AJCC_M age, and tumor size. Thereafter, a nomogram was established based on those independent prognostic factors. The competitive risk model revealed no competitive risk for the cancer specific endpoint event. Those data from 2007 to 2009 were used to validate the results from 2010 to 2016 with general consistency. This retrospective study determined the prognostic factors in patients with conventional chondrosarcoma using the Cox regression hazards model. A nomogram was established to help oncologists assess this rare malignant tumor with low heterogeneity.Conclusions: In the study, independent prognostic risk factors for conventional chondrosarcoma were identified, and a nomogram predicting three- and five- year overall survival rates were established, which may help physicians to predict the prognosis of patients with chondrosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Gao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, chemotherapy and radiotherapy are not the standard therapies for chondrosarcoma. The primary goal is to better understand the characteristics of conventional chondrosarcomas since Amer et al [13,22] reviewed and described nonconventional chondrosarcomas. In the present study, we identi ed prognostic factors of chondrosarcoma by using the data from the SEER database from 2010 to 2016, and the ndings were veri ed using the data from 2007 to 2009.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors in Patients with Conventional Chondrosarcoma: A SEER Database Analysis

Gao

Sun

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Conventional chondrosarcoma, a rare type of bone tumor, is resistant to chemotherapy and radiation therapy. Thus, additional characteristics of this disease are needed to open other treatment modalities. The clinical investigation of chondrosarcoma is limited to small-series and single-institution studies. The Surveillance, Epidemiologic, and End Results (SEER) is the most complete and comprehensive database worldwide. This SEER database study aimed to collect clinicopathological features and determine the prognosis of patients with conventional chondrosarcoma. Methods: Clinicopathologic and survival data of 782 patients from 2010 to 2016 and 353 patients from 2007 to 2009 were downloaded and analyzed. Overall survival was analyzed using the Kaplan–Meier method and verified by univariable Cox regression. Independent prognostic factors were assessed using the multi-variable Cox regression hazards model. A nomogram was established and used to calculate the one-, three-, and five-year survival rates. Competitive risk models were established to identify the prognostic risk factors related to competitive endpoint events in patients with conventional chondrosarcoma. Results: In total, 361 extremities, 360 axial bones, and 61 cranial samples were collected from the 2010–2016 cohort. The median survival time of patients with conventional chondrosarcoma was 35 months, and the independent prognostic factors were sex, grade, surgery, AJCC_M age, and tumor size. Thereafter, a nomogram was established basing from those independent prognostic factors. The competitive risk model revealed no competitive risk for the cancer-specific endpoint event. The data from 2007 to 2009 were used to validate the results from 2010 to 2016 with general consistency. Conclusion: This retrospective study determined the prognostic factors in patients with conventional chondrosarcoma by using the Cox regression hazards model. A nomogram was established to help oncologists assess this rare malignant tumor with low heterogeneity.

show abstract

“…In one case, the combined prosthesis was used to improve dysarthria after stroke. 5 ) In the second case, for which it was used to manage dysphagia and dysarthria after surgery for chondrosarcoma, 6 ) although the improvement of dysarthria was emphasized, improved bolus transit was the only improvement observed for swallowing function. Currently, little is known regarding the effects of integrated PAP and PLP devices on swallowing function.…”

Section: Introductionmentioning

confidence: 99%

A Case of Dysphagia and Dysarthria Improved by Flexible-palatal Lift/augmentation Combination Prosthesis

Hirasaki¹,

Takagi

Umeda

et al. 2023

PRM

View full text Add to dashboard Cite

Background: Palatal augmentation prosthesis (PAP) and palatal lift prosthesis (PLP) have been used to improve dysphagia and dysarthria. However, to date, there are few reports on their combined use. We report a quantitative evaluation of the effectiveness of a flexible-palatal lift/augmentation combination prosthesis (fPL/ACP) based on videofluoroscopic swallowing study (VFSS) and speech intelligibility testing. Case: An 83-year-old woman was admitted to our hospital with a hip fracture. She developed aspiration pneumonia at 1 month after partial hip replacement. Oral motor function tests revealed a motor deficit of the tongue and soft palate. VFSS showed delayed oral transit, nasopharyngeal reflux, and excessive pharyngeal residue. The cause of her dysphagia was assumed to be pre-existing diffuse large B-cell lymphoma and sarcopenia. To improve the dysphagia, an fPL/ACP was fabricated and applied. It improved the patient’s oral and pharyngeal swallowing and speech intelligibility. In addition to prosthetic treatment, rehabilitation and nutritional support allowed her to be discharged. Discussion: The effects of fPL/ACP in the present case were similar to those of flexible-PLP and PAP. f-PLP assists in elevation of the soft palate and improved the nasopharyngeal reflux and hypernasal speech. PAP promotes tongue movement and results in improved oral transit and speech intelligibility. Therefore, fPL/ACP may be effective in patients with motor deficits in both the tongue and soft palate. To maximize the effect of the intraoral prosthesis, a transdisciplinary approach with concurrent swallowing rehabilitation, nutritional support, and physical and occupational therapy is necessary.

show abstract

Prosthetic Rehabilitation with Palatal Lift/Augmentation in a Patient with Neurologic/Motor Deficit Due To Cancer Therapy for Chondrosarcoma

Cited by 9 publications

References 15 publications

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Prognostic Factors in Conventional Chondrosarcoma Patients: a SEER Database Analysis

Prognostic Factors in Patients with Conventional Chondrosarcoma: A SEER Database Analysis

A Case of Dysphagia and Dysarthria Improved by Flexible-palatal Lift/augmentation Combination Prosthesis

Contact Info

Product

Resources

About